[go: up one dir, main page]

UY35650A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
UY35650A
UY35650A UY35650A UY35650A UY35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A UY 35650 A UY35650 A UY 35650A
Authority
UY
Uruguay
Prior art keywords
heterocyclic compound
compound
prophylaxis
obesity
symbol
Prior art date
Application number
UY35650A
Other languages
English (en)
Inventor
Ikoma Minoru
Aida Jumpei
Igawa Hideyuki
Takahashi Masashi
Kakegawa Keiko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY35650A publication Critical patent/UY35650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la p rofilaxis o el tratamiento de la obesidad y similares. Un compuesto representado por la fórmula (I) : en donde cada símbolo está de acuerdo con lo definido en la memoria descriptiva, o una sal del mismo.
UY35650A 2013-07-09 2014-07-08 Compuesto heterocíclico UY35650A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013143940 2013-07-09

Publications (1)

Publication Number Publication Date
UY35650A true UY35650A (es) 2015-02-27

Family

ID=51220851

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35650A UY35650A (es) 2013-07-09 2014-07-08 Compuesto heterocíclico

Country Status (9)

Country Link
US (1) US9199963B2 (es)
EP (1) EP3019487A1 (es)
JP (1) JP2016523809A (es)
CN (1) CN105358544A (es)
AR (1) AR096848A1 (es)
CA (1) CA2917490A1 (es)
TW (1) TW201536767A (es)
UY (1) UY35650A (es)
WO (1) WO2015005489A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6129850B2 (ja) * 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
EP2848621A4 (en) * 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
MX2022007665A (es) 2019-12-20 2022-07-19 Bayer Ag Tiofenocarboxamidas sustituidas y sus derivados.
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
ES2399232T3 (es) 1997-09-05 2013-03-26 Genzyme Corporation Procedimientos para la generación de preparaciones de vectores de AAV recombinantes de títulos altos exentas de auxiliares
EP1042498A4 (en) 1997-12-03 2003-05-07 Smithkline Beecham Corp METHOD FOR SEARCHING FOR AN AGONIST OR ANTAGONIST OF THE HUMAN 11 CB SPLICE VARIANT
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
US7101845B2 (en) 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
SI1490064T1 (sl) 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
AU2003275150A1 (en) 2002-09-25 2004-04-19 Neurogen Corporation Methods for preventing and treating obesity in patients with mc4 receptor mutations
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
WO2005040824A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JPWO2006104136A1 (ja) 2005-03-29 2008-09-11 萬有製薬株式会社 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
EP2431367A3 (en) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
KR20090127867A (ko) 2006-12-05 2009-12-14 네이셔널 치아오 텅 유니버시티 인다졸 화합물
AU2008204915B2 (en) 2007-01-10 2013-02-07 Albany Molecular Research, Inc. 5-furopyridinone substituted indazoles
CA2673654A1 (en) * 2007-01-10 2008-07-17 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
BRPI0807014A2 (pt) 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US20120316200A1 (en) * 2010-04-12 2012-12-13 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
CA2917490A1 (en) 2015-01-15
CN105358544A (zh) 2016-02-24
US20150018373A1 (en) 2015-01-15
EP3019487A1 (en) 2016-05-18
AR096848A1 (es) 2016-02-03
TW201536767A (zh) 2015-10-01
JP2016523809A (ja) 2016-08-12
US9199963B2 (en) 2015-12-01
WO2015005489A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
DOP2016000206A (es) Compuesto heterocíclico fusionado
CR20160368A (es) Compuesto heterocíclico
CL2017003404A1 (es) Compuestos antibacterianos
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY35774A (es) Compuesto heterocíclico
DOP2016000337A (es) Compuestos heterociclicos y su uso como inhibidores de gamma-t del receptor orfano relacionados con retinoide (ror)
MX384501B (es) Tratamiento de artritis psoriasica usando apremilast.
CO2017003699A2 (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
AR096344A1 (es) Compuestos de elastómeros, mezclas y métodos para preparar los mismos
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
MX368954B (es) Insectos modificados para reducir la expresion genica especifica en los testiculos para los metodos de control biologico.
CL2015002358A1 (es) Compuestos bicíclicos.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
UY35650A (es) Compuesto heterocíclico
EA201591709A1 (ru) 5-бром-индирубины
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.
UY37502A (es) Dinucleótido cíclico
BR112016012248A2 (pt) método de tratamento de nefropatia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206